Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Refractive Error, Eye Diseases, Near Vision
Trial Timeline
Dec 19, 2022 → Jan 25, 2024
NCT ID
NCT05656027About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05656027. Target conditions include Presbyopia, Refractive Error, Eye Diseases.
What happened to similar drugs?
1 of 5 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (4)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05656027 | Phase 3 | Completed |
Competing Products
14 competing products in Presbyopia